Nephrogenex to Reach Agreement With FDA for Proposed PYR-311 Interim Analysis Plan By End of Q3; Will Continue to Enroll Patients In Phase 3 Pyridorin Trial, Half of the 600 Patients to be Enrolled By Q1 2015